Journal of Clinical Oncology
Articles in this Issue
Prognostic factors and survival analysis across different age groups in elderly patients with ES-SELC.
e20115 Background: This study aims to investigate the prognostic factors affecting elderly SCLC patients, providing valuable insights to enhance their qua...
The utilization of palliative care services by patients with glioblastoma: A cross-sectional study with care partners of patients with GBM recruited from Facebook support groups.
2076 Background: Glioblastoma(GBM) is a terminal brain cancer that has a rapid onset and results in symptoms such as headaches, vomiting, seizures, anxiet...
Commission on Cancer lung cancer surgery quality metric and overall survival in a population-based cohort.
8067 Background: The American College of Surgeons Commission on Cancer (CoC) quality metric for curative-intent lung cancer surgery, Operative Standard 5....
Epidemiology of liver malignancies in Jordan: A MENA region insight.
e22581 Background: Liver malignancies present a healthcare challenge from late presentations to complex treatment, a rise in prevalence of hepatitis, obes...
An exploratory study to predict the efficacy and prognosis of immunotherapy for extensive-stage small cell lung cancer based on peripheral blood dynamic immune profiles.
2549 Background: The high-dimensional classification information of peripheral blood mononuclear cells can provide abundant efficacy and prognosis-related...
Effects of Akt inhibitors on radiation sensitivity, oxidative stress, EMT reversal, and immune microenvironment reprogramming in pancreatic cancer.
e16462 Background: Locally advanced and borderline resectable pancreatic tumors are treated with multi-agent cytotoxic chemotherapy or chemoradiation ther...
Outcomes of immunotherapy in thymoma: A systematic review and meta-analysis.
e20142 Background: Immunotherapy has emerged as a promising treatment for Thymoma patients, particularly where traditional therapies fail. Thymoma, a tumo...
Two cycles of neoadjuvant therapy with low-dose radiotherapy, PD-1 inhibitor tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma (NeoRTPC02): A phase II, open-label, single-arm trial.
6039 Background: Despite standard treatments, mortality rates remain high in locally advanced head and neck squamous cell carcinoma (LA HNSCC). Neoadjuvan...
ctDNA informed management of metastatic pancreatic cancer.
e16371 Background: Circulating tumor DNA (ctDNA) informs therapeutic decisions and its use in pancreatic cancer is emerging. We explore the adoption of ct...
First-in-human study of AWT020, a bifunctional anti-PD-1/IL-2 fusion protein, in patients with advanced cancer.
e14500 Background: Whileimmune checkpoint inhibitors have become the standard of care for multiple cancer types, resistance to anti-PD-(L)1 therapies rema...
Barbados’ first next-generation sequencing of a prostate cancer sample.
5025 Background: According to the WHO (2022), Prostate cancer is the most frequent of all cancers in Barbados. In 2022, it accounted for over 45% of the r...
Application of quantile regression forest for early detection of sarcopenia in oncogeriatric patients.
e13854 Background: Sarcopenia, characterized by the progressive loss of muscle strength and mass, adversely affects oncological outcomes, treatment tolera...
Comparing mortality risk in patients with malignant melanoma and type 2 diabetes mellitus treated with immunotherapy alone versus immunotherapy plus SGLT2 inhibitors.
e14619 Background: Patients with malignant melanoma (MM) and type 2 diabetes mellitus (T2DM) face treatment challenges due to complex therapy interactions...
Tocilizumab in fibrolamellar carcinoma.
e16252 Background: Fibrolamellar Carcinoma (FLC) is a rare liver cancer of young people. Interleukin-6 (IL-6), is overexpressed in many cancers, including...
ONITT: A phase I study of nanoliposomal irinotecan with talazoparib or temozolomide in children and young adults with recurrent or refractory solid tumors.
10007 Background: Talazoparib (TAL), a potent PARP inhibitor, demonstrated preclinical activity in Ewing sarcoma when combined with irinotecan (IRN) and t...
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma: Subgroup analysis from the phase 3 ETER100 trial.
4536 Background: Dual immune checkpoint inhibitors (ICIs) or ICIs plus VEGF-directed therapies, have been approved as first-line treatment in patients (pt...
Single arm prospective study evaluating the relationship of ctDNA molecular complete response (mCR) and pathologic complete response (pCR) in a diverse early triple-negative breast cancer patient (TNBC) population receiving neoadjuvant chemotherapy (NAC).
e12553 Background: Chemotherapy plus pembrolizumab in neoadjuvant and adjuvant settings (Keynote-522) is standard of care for early-stage triple-negative...
Efficacy and safety of pralsetinib in <i>RET</i> fusion-positive solid tumors: Final data from the ARROW trial.
3116 Background: Pralsetinib is an oral tyrosine kinase inhibitor that selectively and potently targets oncogenic RET fusion and mutation proteins....
Molecular and clinical characterization of KLK2 mRNA expression in prostate cancer (PC).
5050 Background: KLK2 is an androgen-regulated gene that plays a critical role in PC biology. Given the development of KLK-2 targeted therapies, we sought...
Financial toxicity and association with treatment outcomes during pediatric CAR T therapy.
10028 Background: Chimeric antigen receptor T cell (CAR) therapy has revolutionized the treatment of relapsed/refractory pediatric B cell malignancies. Ho...
Rural-urban disparities in gallbladder cancer-related mortality in the United States (1999-2020).
e22544 Background: Gallbladder cancer (GBC) is a rare but aggressive malignancy, accounting for over 50% of biliary tract cancers. The disparities in GBC-...
Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after 2 or more HER2-directed chemotherapies (KM-10A/KCSG BR18-13).
1021 Background: The prognosis of patients with HER2 positive metastatic breast cancer (MBC) has dramatically improved with the advent of HER2-targeted th...
Phase 1 study of gotistobart (BNT316/ONC-392) in combination with lutetium Lu 177 vipivotide tetraxetan (Lu 177) in patients with metastatic castration-resistant prostate cancer (mCRPC).
5067 Background: When used in combination with physician’s choice of care, Lu 177 showed significant PFS and OS improvements in mCRPC. Combinations with n...
IMMUNORARE <sup>5</sup> : A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers—The Gestational Trophoblastic Tumors Cohort.
TPS5636 Background: For patients with rare cancers, there is an unmet medical need to investigate innovative therapeutics beyond standard first-line treat...
Neuropsychiatric disorders among patients with breast cancer during the COVID-19 pandemic.
e23061 Background: A diagnosis of breast cancer can be detrimental to a patient’s neuropsychiatric health even with advancements in cancer tr...